Modulating the Function of ATP-binding Cassette Subfamily G Member 2 (ABCG2) with Inhibitor Cabozantinib

Overview

Journal Pharmacol Res

Publisher Elsevier

Specialty Pharmacology

Date 2017 Jan 30

PMID 28131876

Citations 13

Authors

Guan-Nan Zhang

Yun-Kai Zhang

Yi-Jun Wang

Anna Maria Barbuti

Xi-Jun Zhu

Xin-Yue Yu

Ai-Wen Wen

John N D Wurpel

Zhe-Sheng Chen

Affiliations

Soon will be listed here.

Abstract

Cabozantinib (XL184) is a small molecule tyrosine kinase receptor inhibitor, which targets c-Met and VEGFR2. Cabozantinib has been approved by the Food and Drug Administration to treat advanced medullary thyroid cancer and renal cell carcinoma. In the present study, we evaluated the ability of cabozantinib to modulate the function of the ATP-binding cassette subfamily G member 2 (ABCG2) by sensitizing cells that are resistant to ABCG2 substrate antineoplastic drugs. We used a drug-selected resistant cell line H460/MX20 and three ABCG2 stable transfected cell lines ABCG2-482-R2, ABCG2-482-G2, and ABCG2-482-T7, which overexpress ABCG2. Cabozantinib, at non-toxic concentrations (3 or 5μM), sensitized the ABCG2-overexpressing cells to mitoxantrone, SN-38, and topotecan. Our results indicate that cabozantinib reverses ABCG2-mediated multidrug resistance by antagonizing the drug efflux function of the ABCG2 transporter instead of downregulating its expression. The molecular docking analysis indicates that cabozantinib binds to the drug-binding site of the ABCG2 transporter. Overall, our findings demonstrate that cabozantinib inhibits the ABCG2 transporter function and consequently enhances the effect of the antineoplastic agents that are substrates of ABCG2. Cabozantinib may be a useful agent in anticancer treatment regimens for patients who are resistant to ABCG2 substrate drugs.

Citing Articles

c-MET tyrosine kinase inhibitors reverse drug resistance mediated by the ATP-binding cassette transporter B1 (ABCB1) in cancer cells.

Nazari S, Poustforoosh A, Paul P, Kukreti R, Tavakkoli M, Saso L 3 Biotech. 2024; 15(1):2.

PMID: 39650809 PMC: 11618280. DOI: 10.1007/s13205-024-04162-9.

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma.

Astore S, Baciarello G, Cerbone L, Calabro F Cancer Drug Resist. 2023; 6(3):517-546.

PMID: 37842234 PMC: 10571064. DOI: 10.20517/cdr.2023.33.

Amelioration of pain and anxiety in sleep-deprived rats by intra-amygdala injection of cinnamaldehyde.

Hadeiy S, Habtemariam S, Shankayi Z, Shahyad S, Sahraei H, Rezaei M Sleep Med X. 2023; 5:100069.

PMID: 37424741 PMC: 10323214. DOI: 10.1016/j.sleepx.2023.100069.

Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein-protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells.

Cheng S, Yang G, Wang W, Ma D, Leung C Genes Dis. 2022; 9(6):1674-1688.

PMID: 36157485 PMC: 9485199. DOI: 10.1016/j.gendis.2021.06.005.

New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-]pyrimidine Tyrosine Kinase Inhibitors.

Podolski-Renic A, Dinic J, Stankovic T, Tsakovska I, Pajeva I, Tuccinardi T Cancers (Basel). 2021; 13(21).

PMID: 34771471 PMC: 8582576. DOI: 10.3390/cancers13215308.

References

Friesner R, Murphy R, Repasky M, Frye L, Greenwood J, Halgren T . Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006; 49(21):6177-96. DOI: 10.1021/jm051256o. View

Sharom F . ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2007; 9(1):105-27. DOI: 10.2217/14622416.9.1.105. View

Patel A, Tiwari A, Chufan E, Sodani K, Anreddy N, Singh S . PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemother Pharmacol. 2013; 72(1):189-99. PMC: 8366681. DOI: 10.1007/s00280-013-2184-z. View

Tiwari A, Sodani K, Dai C, Abuznait A, Singh S, Xiao Z . Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett. 2012; 328(2):307-17. PMC: 3513659. DOI: 10.1016/j.canlet.2012.10.001. View

Zhang Y, Zhang H, Zhang G, Wang Y, Kathawala R, Si R . Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents. Oncotarget. 2015; 6(27):24277-90. PMC: 4695185. DOI: 10.18632/oncotarget.4493. View

Mao Q, Unadkat J . Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005; 7(1):E118-33. PMC: 2751502. DOI: 10.1208/aapsj070112. View

Wang Y, Huang Y, Anreddy N, Zhang G, Zhang Y, Xie M . Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. Oncotarget. 2015; 7(5):5877-91. PMC: 4868728. DOI: 10.18632/oncotarget.6711. View

Guo H, Zhang G, Wang Y, Zhang Y, Sodani K, Talele T . β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. Oncol Rep. 2013; 31(2):858-66. DOI: 10.3892/or.2013.2870. View

Zhang H, Kathawala R, Wang Y, Zhang Y, Patel A, Shukla S . Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. Int J Biochem Cell Biol. 2014; 51:111-9. PMC: 7670583. DOI: 10.1016/j.biocel.2014.03.026. View

10.

Wang D, Patel A, Shukla S, Zhang Y, Wang Y, Kathawala R . Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget. 2014; 5(12):4529-42. PMC: 4147343. DOI: 10.18632/oncotarget.2102. View

11.

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

12.

Zhang Y, Zhang G, Wang Y, Patel B, Talele T, Yang D . Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. Sci Rep. 2016; 6:25694. PMC: 4860574. DOI: 10.1038/srep25694. View

13.

Zhang Y, Wang Y, Gupta P, Chen Z . Multidrug Resistance Proteins (MRPs) and Cancer Therapy. AAPS J. 2015; 17(4):802-12. PMC: 4476997. DOI: 10.1208/s12248-015-9757-1. View

14.

Huber S, Wege A, Bernhardt G, Buschauer A, Brockhoff G . Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity. Cytometry A. 2015; 87(8):707-16. DOI: 10.1002/cyto.a.22675. View

15.

Cole S, Chanda E, Dicke F, Gerlach J, Mirski S . Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res. 1991; 51(13):3345-52. View

16.

Zhang H, Patel A, Ma S, Li X, Zhang Y, Yang P . In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1. Br J Pharmacol. 2014; 171(24):5845-57. PMC: 4290721. DOI: 10.1111/bph.12889. View

17.

Smith M, Sweeney C, Corn P, Rathkopf D, Smith D, Hussain M . Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014; 32(30):3391-9. PMC: 4383838. DOI: 10.1200/JCO.2013.54.5954. View

18.

Zhou W, Zhang X, Cheng C, Wang F, Wang X, Liang Y . Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol. 2012; 166(5):1669-83. PMC: 3419910. DOI: 10.1111/j.1476-5381.2012.01849.x. View

19.

De Bruin M, Miyake K, Litman T, Robey R, Bates S . Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 2000; 146(2):117-26. DOI: 10.1016/s0304-3835(99)00182-2. View

20.

Ross D, Yang W, Abruzzo L, Dalton W, Schneider E, Lage H . Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 1999; 91(5):429-33. DOI: 10.1093/jnci/91.5.429. View